Capital Square LLC Has $589,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Capital Square LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 3,758 shares of the company’s stock after selling 305 shares during the period. Capital Square LLC’s holdings in Johnson & Johnson were worth $589,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Harbor Investment Advisory LLC raised its holdings in shares of Johnson & Johnson by 2.4% during the 4th quarter. Harbor Investment Advisory LLC now owns 47,947 shares of the company’s stock valued at $7,515,000 after purchasing an additional 1,116 shares in the last quarter. Custom Index Systems LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $433,000. Aspiriant LLC raised its holdings in Johnson & Johnson by 0.8% during the fourth quarter. Aspiriant LLC now owns 22,978 shares of the company’s stock valued at $3,602,000 after buying an additional 177 shares in the last quarter. Hendershot Investments Inc. lifted its position in shares of Johnson & Johnson by 4.9% in the fourth quarter. Hendershot Investments Inc. now owns 145,812 shares of the company’s stock worth $22,855,000 after buying an additional 6,849 shares during the last quarter. Finally, GW Henssler & Associates Ltd. boosted its stake in shares of Johnson & Johnson by 4.8% during the 4th quarter. GW Henssler & Associates Ltd. now owns 2,376 shares of the company’s stock worth $372,000 after acquiring an additional 108 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. Morgan Stanley reduced their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday. Raymond James lifted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.31.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $144.45 on Wednesday. The firm has a market capitalization of $348.09 billion, a price-to-earnings ratio of 10.46, a PEG ratio of 2.48 and a beta of 0.53. Johnson & Johnson has a one year low of $143.39 and a one year high of $175.97. The business has a fifty day simple moving average of $156.80 and a 200 day simple moving average of $155.82. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter in the prior year, the company posted $2.68 EPS. The business’s revenue was up 2.3% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Insider Transactions at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.